If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

New PREtec Products Announced

28 Sep 2023 07:00

RNS Number : 8895N
Plant Health Care PLC
28 September 2023
 

28 September 2023

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

New PREtec Products Announced

 

Brazilian Launch of MOSHY™ and TEIKKO™ planned

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce two new brands - MOSHY and TEIKKO - derived from the Company's PREtec technology platform (Vaccines for PlantsTM) for launch in Brazil for the 2024 soybean growing season.

 

Highlights:

 

· MOSHY (PHC25279) is a foliar product registered in Brazil to control foliar diseases in coffee and sugar cane.

· TEIKKO (PHC68949) is a seed treatment to control harmful soil nematodes in soybean fields. This is expected to be registered in Brazil before the end of 2023.

· MOSHY and TEIKKO add to the portfolio of Plant Health Care products available to growers in Brazil.

· Discussions with potential Brazilian distributors of MOSHY and TEIKKO are ongoing.

· For the six months ended 30 June 2023, revenue in Brazil was up 48%, driven by in-market demand for H2Copla® (Harpinαβ) and Saori® (PREtec).

 

MOSHY and TEIKKO provide specific benefits for growers of improved disease and nematode control, plant health and yield.

 

MOSHY helps control a broad spectrum of plant diseases when used as part of an integrated disease control program. MOSHY was shown to reduce the incidence and severity of sugar cane orange rust and coffee leaf rust leading to significant increases in yield. Brazil is the world's largest producer of sugar cane and coffee. As part of Plant Health Care's continued investment in Brazilian agriculture, additional crop specific, plant pathogen claims will be added to the MOSHY product label, allowing use on a wider range of crops.

 

TEIKKO is a novel product that amplifies a plant's natural defense pathways to provide protection against plant parasitic nematodes which damage plant roots and limit crop yield. TEIKKO was submitted as a seed treatment for the control of root-lesion nematode (Pratylenchus brachyurus) in soybean. Research carried out during the 2021/22 and 2022/23 soybean crop seasons showed that TEIKKO controlled Pratylenchus brachyurus in soybeans, with similar or superior performance when compared to standard market treatments. For the 2023/24 season, the soybean harvested area in Brazil is forecast to be 45.6 million hectares. Additional crops and nematode species will be added to the TEIKKO product label further expanding its potential use.

 

Both products are based on the Company's innovative PREtec technology platform. Derived from natural proteins, PREtec is an environmentally friendly technology which stimulates plant defense and pathogen resistance mechanisms within plants, resulting in improved crop growth and quality along with the ability to withstand a variety of abiotic stresses. 

 

As well as launching new products in its existing markets, Plant Health Care continues to expand into new markets around the world and is growing its relationships with major global distribution partners. As a result, the Company is on track to achieve revenue of $30 million by 2025.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Plant Health Care continues to scale our global business with the addition of TEIKKO and MOSHY to the Brazil product line which includes H2Copla and Saori. Plant Health Care's biological products have earned the reputation of contributing to sustainable agriculture while increasing yields, controlling diseases, and generating a positive ROI for growers. We expect MOSHY and TEIKKO to be novel biological products that will deliver control of nematodes and diseases in critical Brazil crops. These new product launches are key steps for Plant Health Care in meeting our $30 million revenue target by 2025."

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

+1 919 926 1600

Cavendish Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

+44 (0) 131 220 9771

SEC Newgate - Financial Communications Robin Tozer / Harry Handyside / George Esmond

+44 (0)7540 106 366 phc@secnewgate.co.uk

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLBUGDCISDDGXR
Date   Source Headline
27th Sep 20075:19 pmRNSDirector/PDMR Shareholding
27th Sep 20077:01 amRNSPlacing
24th Sep 20077:03 amRNSHalf Year Results
24th Sep 20077:02 amRNSMyconate Trial Results
31st Aug 200710:14 amRNSTotal Voting Rights
28th Aug 20071:00 pmRNSStock Award
23rd Aug 200710:14 amRNSNotice of Results
13th Aug 20074:15 pmRNSAIM Rule 26 Information
13th Aug 200711:55 amRNSHolding(s) in Company
13th Aug 20078:49 amRNSHolding(s) in Company
31st Jul 200711:39 amRNSTotal Voting Rights
27th Jul 20077:01 amRNSN-Hibit Trial Results
25th Jul 20071:38 pmRNSAdditional Listing
23rd Jul 200711:35 amRNSDirector/PDMR Shareholding
2nd Jul 20072:25 pmRNSTotal Voting Rights
27th Jun 20077:01 amRNSProduct Update
11th Jun 20075:53 pmRNSHolding(s) in Company
8th Jun 20075:03 pmRNSAGM Statement
4th Jun 20077:31 amRNSTotal Voting Rights
17th May 20077:01 amRNSBoard Change
14th May 20077:00 amRNSNotice of AGM
1st May 20073:25 pmRNSTotal Voting Rights
26th Apr 20079:23 amRNSAnnual Report and Accounts
19th Apr 20071:22 pmRNSDirector/PDMR Shareholding
18th Apr 20075:42 pmRNSDirector/PDMR Shareholding
16th Apr 20077:02 amRNSFinal Results
16th Apr 20077:02 amRNSSuccessful Trial Results
30th Mar 20074:54 pmRNSTotal Voting Rights
30th Mar 20074:51 pmRNSHolding(s) in Company
23rd Mar 20076:19 pmRNSHolding(s) in Company
13th Mar 20079:01 amRNSNotice of Results
5th Mar 20075:36 pmRNSExercise of Options
5th Mar 20075:20 pmRNSHolding(s) in Company
5th Mar 20078:04 amRNSHolding(s) in Company
1st Mar 20073:33 pmRNSTotal Voting Rights
1st Mar 20077:04 amRNSRe Acquisition
15th Feb 20079:04 amRNSPartnership
8th Feb 200712:13 pmRNSAdditional Listing
6th Feb 20075:52 pmRNSAdditional Listing
5th Feb 200710:19 amRNSHolding(s) in Company
2nd Feb 20078:40 amRNSHolding(s) in Company
31st Jan 20077:01 amRNSDirector/PDMR Shareholding
24th Jan 200712:01 pmRNSHolding(s) in Company
19th Jan 200712:24 pmRNSTotal Voting Rights
18th Jan 20076:06 pmRNSDirector/PDMR Shareholding
17th Jan 20077:01 amRNSMyconate Agreement
17th Jan 20077:01 amRNSTrading Statement
15th Jan 200710:42 amRNSMyconate Update
5th Jan 20079:01 amRNSExercise of Options
20th Dec 20064:14 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.